A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells

Molecular Systems Biology

Volumn 11, Issue 12, 2015, Pages

  Breinig, Marco ^a,b   Klein, Felix A ^c   Huber, Wolfgang ^c   Boutros, Michael ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

compound mode of action; drug synergism; high content imaging; isogenic cell lines; systems pharmacology

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMSACRINE; AZACITIDINE; BENDAMUSTINE; COLCHICINE; DIMETHYL SULFOXIDE; DISULFIRAM; ETOPOSIDE; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; NICLOSAMIDE; NOCODAZOLE; OUABAIN; PHENANTHROLINE; ROTTLERIN; TYRPHOSTIN; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL; CANCER CELL LINE; CELL GROWTH; CHEMICAL INTERACTION; GENE INTERACTION; GENE MUTATION; GENETIC BACKGROUND; HIGH THROUGHPUT SCREENING; HUMAN; IMAGE ANALYSIS; MOLECULE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HCT 116 CELL LINE; MOLECULAR IMAGING; NEOPLASM; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION; HCT116 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR IMAGING; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84955508486     PISSN: None     EISSN: 17444292     Source Type: Journal    
DOI: 10.15252/msb.20156400     Document Type: Article

References (59)

1. Al-Lazikani B, Banerji U, Workman P, (2012) Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30: 679-692
2. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, et al, (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607
3. Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, et al, (2013) An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154: 1151-1161
4. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57: 289-300
5. Bliesath J, Huser N, Omori M, Bunag D, Proffitt C, Streiner N, Ho C, Siddiqui-Jain A, O'Brien SE, Lim JKC, Ryckman DM, Anderes K, Rice WG, Drygin D, (2012) Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett 322: 113-118
6. Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, Bruggner RV, Simonds EF, Bendall SC, Sachs K, Krutzik PO, Nolan GP, (2012) Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol 30: 858-867
7. Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G, Whitebread S, (2012) Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov 11: 909-922
8. Caie PD, Walls RE, Ingleston-Orme A, Daya S, Houslay T, Eagle R, Roberts ME, Carragher NO, (2010) High-content phenotypic profiling of drug response signatures across distinct cancer cells. Mol Cancer Ther 9: 1913-1926
9. Cao Y, Charisi A, Cheng L-C, Jiang T, Girke T, (2008) ChemmineR: a compound mining framework for R. Bioinformatics 24: 1733-1734
10. Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos Simoes R, Carugo O, Baccarini M, (2009) A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol 16: 294-303
11. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW, (2002) Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci USA 99: 8265-8270
12. Christman JK, (2002) 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21: 5483-5495
13. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, Nergiz ME, Costanzo M, Baryshnikova A, Giaever G, Nislow C, Myers CL, Andrews BJ, Boone C, Roth FP, (2011) Systematic exploration of synergistic drug pairs. Mol Syst Biol 7: 544
14. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JLY, Toufighi K, Mostafavi S, Prinz J, St Onge RP, VanderSluis B, Makhnevych T, Vizeacoumar FJ, Alizadeh S, Bahr S, Brost RL, Chen Y, Cokol M, et al, (2010) The genetic landscape of a cell. Science 327: 425-431
15. Crider KS, Yang TP, Berry RJ, Bailey LB, (2012) Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr 3: 21-38
16. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA, Ruzzene M, (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12: 668-677
17. Ding W, Shanafelt TD, Lesnick CE, Erlichman C, Leis JF, Secreto C, Sassoon TR, Call TG, Bowen DA, Conte M, Kumar S, Kay NE, (2013) Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. Br J Haematol 164: 146-150
18. Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B, Papadopoulos N, (2010) Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci USA 107: 2598-2603
19. Fuchs F, Pau G, Kranz D, Sklyar O, Budjan C, Steinbrink S, Horn T, Pedal A, Huber W, Boutros M, (2010) Clustering phenotype populations by genome-wide RNAi and multiparametric imaging. Mol Syst Biol 6: 370
20. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, et al, (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575
21. Gustafsdottir SM, Ljosa V, Sokolnicki KL, Anthony Wilson J, Walpita D, Kemp MM, Petri Seiler K, Carrel HA, Golub TR, Schreiber SL, Clemons PA, Carpenter AE, Shamji AF, (2013) Multiplex cytological profiling assay to measure diverse cellular states. PLoS ONE 8: e80999
22. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690
23. Horn T, Sandmann T, Fischer B, Axelsson E, Huber W, Boutros M, (2011) Mapping of signaling networks through synthetic genetic interaction analysis by RNAi. Nat Methods 8: 341-346
24. Huber W, von Heydebreck A, Sültmann H, Poustka A, Vingron M, (2002) Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 (Suppl. 1): S96-S104
25. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, di Bernardo D, (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 107: 14621-14626
26. Keating MJ, Bach C, Yasothan U, Kirkpatrick P, (2008) Bendamustine. Nat Rev Drug Discov 7: 473-474
27. Kisselev AF, van der Linden WA, Overkleeft HS, (2012) Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19: 99-115
28. Kittanakom S, Arnoldo A, Brown KR, Wallace I, Kunavisarut T, Torti D, Heisler LE, Surendra A, Moffat J, Giaever G, Nislow C, (2013) Miniature short hairpin RNA screens to characterize antiproliferative drugs. G3 3: 1375-1387
29. Kleinstreuer NC, Yang J, Berg EL, Knudsen TB, Richard AM, Martin MT, Reif DM, Judson RS, Polokoff M, Dix DJ, Kavlock RJ, Houck KA, (2014) Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat Biotechnol 32: 583-591
30. Kranz D, Boutros M, (2014) A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. EMBO J 33: 181-197
31. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR, (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935
32. Laufer C, Fischer B, Billmann M, Huber W, Boutros M, (2013) Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. Nat Methods 10: 427-431
33. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC, (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14: 309-317
34. Lord CJ, Ashworth A, (2010) Biology-driven cancer drug development: back to the future. BMC Biol 8: 38
35. Lövborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, Larsson R, (2006) Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer 118: 1577-1580
36. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK, (2006) Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol 2: 329-337
37. Maskey D, Yousefi S, Schmid I, Zlobec I, Perren A, Friis R, Simon H-U, (2013) ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun 4: 2130
38. Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H, Craig-Mueller N, Colinge J, Duernberger G, Nijman SMB, (2011) A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol 7: 787-793
39. Oppenheim EW, Nasrallah IM, Mastri MG, Stover PJ, (2000) Mimosine is a cell-specific antagonist of folate metabolism. J Biol Chem 275: 19268-19274
40. Parsons AB, Lopez A, Givoni IE, Williams DE, Gray CA, Porter J, Chua G, Sopko R, Brost RL, Ho C-H, Wang J, Ketela T, Brenner C, Brill JA, Fernandez GE, Lorenz TC, Payne GS, Ishihara S, Ohya Y, Andrews B, et al, (2006) Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126: 611-625
41. Pau G, Fuchs F, Sklyar O, Boutros M, Huber W, (2010) EBImage-an R package for image processing with applications to cellular phenotypes. Bioinformatics 26: 979-981
42. Pelz O, Gilsdorf M, Boutros M, (2010) web cellHTS2: a web-application for the analysis of high-throughput screening data. BMC Bioinformatics 11: 185
43. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ, (2004) Multidimensional drug profiling by automated microscopy. Science 306: 1194-1198
44. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE, (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573
45. Sander JD, Joung JK, (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32: 347-355
46. Scholl FA, Dumesic PA, Barragan DI, Harada K, Charron J, Khavari PA, (2009) Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. Cancer Res 69: 3772-3778
47. Sero JE, Sailem HZ, Ardy RC, Almuttaqi H, Zhang T, Bakal C, (2015) Cell shape and the microenvironment regulate nuclear translocation of NF-κB in breast epithelial and tumor cells. Mol Syst Biol 11: 790
48. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T, (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504
49. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3
50. Soltoff SP, (2001) Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and indirectly blocks protein kinase Cdelta tyrosine phosphorylation. J Biol Chem 276: 37986-37992
51. Sorger PK, Allerheiligen SRB, Abernethy DR, Altman RB, Brouwer KLR, Califano A, Iyengar R, Jusko WJ, Lauffenburger DA, (2011) Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. NIH White Pap. QSP Workshop Group-Oct. 2011
52. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV, (2006) Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2: 474-479
53. Tan X, Hu L, Luquette LJ III, Gao G, Liu Y, Qu H, Xi R, Lu ZJ, Park PJ, Elledge SJ, (2012) Systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol 30: 1125-1130
54. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW, (2001) Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 19: 940-945
55. Torres J, Pulido R, (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276: 993-998
56. Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JTF, Kwan JHM, Sayad A, Mero P, Lawo S, Tanaka H, Brown KR, Baryshnikova A, Mak AB, Fedyshyn Y, Wang Y, Brito GC, Kasimer D, Makhnevych T, Ketela T, et al, (2013) A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol Syst Biol 9: 696
57. Wang X, Yue P, Chan C-B, Ye K, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Fu H, Khuri FR, Sun S-Y, (2007) Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 27: 7405-7413
58. Weinbach EC, Garbus J, (1969) Mechanism of action of reagents that uncouple oxidative phosphorylation. Nature 221: 1016-1018
59. Young DW, Bender A, Hoyt J, McWhinnie E, Chirn G-W, Tao CY, Tallarico JA, Labow M, Jenkins JL, Mitchison TJ, Feng Y, (2008) Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol 4: 59-68